ATE387498T1 - Therapeutische pde4d phosphodiesterase inhibitoren - Google Patents

Therapeutische pde4d phosphodiesterase inhibitoren

Info

Publication number
ATE387498T1
ATE387498T1 AT99968130T AT99968130T ATE387498T1 AT E387498 T1 ATE387498 T1 AT E387498T1 AT 99968130 T AT99968130 T AT 99968130T AT 99968130 T AT99968130 T AT 99968130T AT E387498 T1 ATE387498 T1 AT E387498T1
Authority
AT
Austria
Prior art keywords
therapeutic
phosphodiesterase
useful
phosphodiesterase inhibitors
pde4d phosphodiesterase
Prior art date
Application number
AT99968130T
Other languages
English (en)
Inventor
Roderic Dale
Amy Arrow
Terry Thompson
Original Assignee
Oligos Etc Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oligos Etc Inc filed Critical Oligos Etc Inc
Application granted granted Critical
Publication of ATE387498T1 publication Critical patent/ATE387498T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
AT99968130T 1998-12-30 1999-12-15 Therapeutische pde4d phosphodiesterase inhibitoren ATE387498T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22358698A 1998-12-30 1998-12-30
US36462699A 1999-07-29 1999-07-29

Publications (1)

Publication Number Publication Date
ATE387498T1 true ATE387498T1 (de) 2008-03-15

Family

ID=26917934

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99968130T ATE387498T1 (de) 1998-12-30 1999-12-15 Therapeutische pde4d phosphodiesterase inhibitoren

Country Status (8)

Country Link
US (1) US20030045490A1 (de)
EP (1) EP1141278B1 (de)
JP (1) JP4787409B2 (de)
AT (1) ATE387498T1 (de)
AU (1) AU781577B2 (de)
CA (1) CA2357950C (de)
DE (1) DE69938256D1 (de)
WO (1) WO2000040714A2 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7833529B1 (en) 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
US20030054531A1 (en) * 2001-03-19 2003-03-20 Decode Genetics Ehf, Human stroke gene
IL159722A0 (en) * 2001-07-10 2004-06-20 Oligos Etc Inc Pharmaceutical compositions containing oligonucleotides
WO2004022701A2 (en) * 2001-07-15 2004-03-18 Keck Graduate Institute Exponential amplification of nucleic acids using nicking agents
FR2828693B1 (fr) * 2001-08-14 2004-06-18 Exonhit Therapeutics Sa Nouvelle cible moleculaire de la neurotoxicite
CA2499320A1 (en) * 2002-09-25 2004-04-08 Decode Genetics Ehf. Susceptibility gene for human stroke; methods of treatment
WO2004042076A2 (en) * 2002-11-08 2004-05-21 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human phosphodiesterase 4a (pde4a)
AU2003301894A1 (en) * 2002-11-08 2004-06-07 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human phosphodiesterase 4d (pde4d)
NZ546521A (en) * 2003-09-29 2009-09-25 Topigen Pharma Inc Oligonucleotide compositions and methods for treating disease including inflammatory conditions
AR059025A1 (es) * 2005-08-09 2008-03-12 Zymogenetics Inc Metodos para el tratamiento y prevencion de proliferacion de celulas anormales utilizando moleculas de fusion taci
JP2009507777A (ja) * 2005-08-09 2009-02-26 ザイモジェネティクス，インコーポレイティド ＴＡＣＩ−Ｉｇ融合分子を用いたＢ細胞性腫瘍の処置方法
AU2006304787A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
US8673873B1 (en) * 2005-12-28 2014-03-18 Alcon Research, Ltd. RNAi-mediated inhibition of phosphodiesterase type 4 for treatment of cAMP-related ocular disorders
EA015342B1 (ru) 2006-05-15 2011-06-30 Арес Трейдинг С.А. Способы лечения аутоиммунных заболеваний с использованием слитой молекулы taci-ig
KR20090035662A (ko) 2006-05-19 2009-04-10 토피겐 파마슈티컬스 인코포레이티드 포스포디에스테라아제의 발현에 영향을 미치는 올리고누클레오티드
WO2008137776A2 (en) * 2007-05-02 2008-11-13 Sirna Therapeutics, Inc. Rna interference mediated inhibition of cyclic nucleotide type 4 phosphodiesterase (pde4b) gene expression using short interfering nucleic acid (sina)
US20100120895A1 (en) * 2007-05-02 2010-05-13 Merck & Co., Inc. RNA Interference Mediated Inhibition of Cyclic Nucleotide Type 4 Phosphodiesterase (PDE4B) Gene Expression Using Short Interfering Nucleic Acid (siNA)
WO2008137771A2 (en) * 2007-05-02 2008-11-13 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF CYCLIC NUCLEOTIDE TYPE 4 PHOSPHODIESTERASE ( PDE4B) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US20100137405A1 (en) * 2007-05-02 2010-06-03 Merck & Co., Inc RNA Interference Mediated Inhibition of Cyclic Nucleotide Type 4 Phosphodiesterase (PDE4B) Gene Expression Using Short Interfering Nucleic Acid (siNA)
US8244352B2 (en) * 2008-06-19 2012-08-14 Cardiac Pacemakers, Inc. Pacing catheter releasing conductive liquid
EP3880256A4 (de) * 2018-11-14 2022-08-03 The Board of Trustees of the Leland Stanford Junior University Targeting von makapp-pde4d3-komplexen bei neurodegenerativen erkrankungen

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0813274B2 (ja) * 1990-08-13 1996-02-14 アイシス・ファーマシューティカルス・インコーポレーテッド 遺伝子発現を検出及び変調する糖修飾されたオリゴヌクレオチド
IL108206A0 (en) * 1993-01-06 1994-04-12 Univ Johns Hopkins Oligomers having improved stability at acid ph
US5510239A (en) * 1993-10-18 1996-04-23 Isis Pharmaceuticals, Inc. Oligonucleotide modulation of multidrug resistance-associated protein
EP0746619A1 (de) * 1994-12-23 1996-12-11 Celltech Therapeutics Limited Menschliche phosphodiesterase typ ivc, ihre herstellung und verwendung
AU705690B2 (en) * 1995-05-19 1999-05-27 Kyowa Hakko Kogyo Co. Ltd. Oxygen-containing heterocyclic compounds
US5849902A (en) * 1996-09-26 1998-12-15 Oligos Etc. Inc. Three component chimeric antisense oligonucleotides
WO2000040592A1 (en) * 1998-12-30 2000-07-13 Oligos Etc. Inc. Acid stable backbone modified end-blocked nucleic acids and therapeutic uses thereof

Also Published As

Publication number Publication date
JP2002534086A (ja) 2002-10-15
US20030045490A1 (en) 2003-03-06
DE69938256D1 (de) 2008-04-10
AU781577B2 (en) 2005-06-02
EP1141278A2 (de) 2001-10-10
CA2357950A1 (en) 2000-07-13
CA2357950C (en) 2013-07-23
JP4787409B2 (ja) 2011-10-05
AU2480800A (en) 2000-07-24
WO2000040714A2 (en) 2000-07-13
EP1141278B1 (de) 2008-02-27
WO2000040714A3 (en) 2000-11-02

Similar Documents

Publication Publication Date Title
ATE387498T1 (de) Therapeutische pde4d phosphodiesterase inhibitoren
WO2003008576A3 (de) Synthetische doppelsträngige oligonucleotide zur gezielten hemmung der genexpression
BR0214309A (pt) Derivados aril-1,4-pirazina substituìdos
BR9408174A (pt) Compostos isoxazolina como agentes antiinflamatórios
ATE380029T1 (de) Prodrugs von gaba-analoga, zusammensetzungen und ihre verwendungszwecke
IS2879B (is) a-(N-súlfonamíðó)asetamíðafleiður sem ß-amýlóíðtálmar
DE60324183D1 (en) Aryl-, aryloxy- und alkyloxysubstituierte 1h-indol-3-yl-glyoxylsäurederivateals inhibitoren des plasminogenaktivatorinhibitors-1 (pai-1)
NO20034056L (no) Kombinasjoner av epotilonanaloger og kjemoterapeutiske midler for behandling av proliferative sykdommer
ATE187447T1 (de) 3-phenyl-2-isoxazoline derivate als entzündugshemmende mittel
NO995544D0 (no) Forbindelser og metoder for inhibering av ekspresjonen av VCAM-1
WO2005019190A3 (en) (4 -amino -1,2, 5-oxadiazol-4-yl) -hetξroaromatic compounds useful as protein kinase inhibitors
SE9800836D0 (sv) New Compounds
PL351125A1 (en) Derivatives of 4,5-diaryl-3(2)-furanone as inhibitors of cykoxygenease-2
NO20043085L (no) Fremgangsmater og sammensetninger for behandling av forstyrrelser i sentralnervesystemet
WO2003057670A3 (en) Indoles as naaladase inhibitors
HUP0003852A2 (hu) Erősen szelektív butiril-kolin-észteráz inhibitorok alkalmazása Alzheimer-kór és elmebaj kezelésére és diagnosztizálására
WO2005014814A3 (en) 5’-and 3’-capped aptamers and uses therefor
WO2003089622A3 (en) Novel genes, compositions, and methods for modulating the unfolded protein response
MXPA03010328A (es) Acidos hidroxinamicos y acil hidroxaminasas como inhibidores de naaladasa.
SE9503117D0 (sv) Novel use of padlock probes
DE60129433D1 (de) Regulation des lipidniveaus über die gene zmax1 oder hbm
PT1254905E (pt) 4-(2-piridil) piperizinas possuindo actividade agonista do receptor 5ht7
SE9804126D0 (sv) New pharmaceutical composition
HUP0100044A1 (hu) A humán Ha-ras gén egy szakaszával komplementer, módosított antiszensz oligonukleotidok
WO2005039480A3 (en) AChE ANTISENSE DEOXYOLIGONUCLEOTIDE AS AN ANTI-INFLAMMATORY AGENT

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties